U.S., Aug. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07740291) titled 'Tirzepatide Impact Assessment Study' on July 28.
Brief Summary: This study examines how two different weight-loss strategies affect heart and metabolic health, as well as changes at the molecular level in the body. One group includes adults who are starting a GLP-1 receptor agonist medication (i.e., semaglutide or tirzepatide) prescribed by their own doctor for weight loss. The other group includes adults who will participate in a structured lifestyle program combining a reduced-calorie diet with increased physical activity. Both groups complete assessments at the start of the study and again after three months.
At each visit, parti...